Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,684 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Tucson, ArizonaAges 18 years+ - NCT05326620Recruiting
Renal cancer patients join a Dutch research kidney study
This study enrolls people newly diagnosed with kidney cancer (including when it has spread) to help build research resources for future kidney cancer care. If you qualify, your information may be used to better understand outcomes and improve treatments.
Amsterdam, North HollandAges 18 years+ - NCT05333523RecruitingPhase 3
Personalized neck radiation using a lymph node sentinel biopsy
This Phase 3 trial tests whether guiding neck radiation by checking the “sentinel” lymph node can target treatment more precisely in certain larynx, hypopharynx, or oropharynx cancers. It aims to improve control while potentially reducing unnecessary radiation to areas that don’t need it.
AmsterdamAges 18 years+ - NCT05338931RecruitingPhase 1/Phase 2
AT101 for relapsed or refractory B-cell lymphoma patients
This trial studies AT101 to see how safe it is, what side effects it causes, and whether it can help people with B-cell non-Hodgkin lymphoma that has come back or did not respond to treatment. It may be an option if your usual treatments are no longer working or aren’t suitable for you.
SeoulAges 19 years+ - NCT05361174RecruitingPhase 1/Phase 2
Testing an IOV-4001 infusion for advanced melanoma or lung cancer
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
Los Angeles, CaliforniaAges 18–70 - NCT05370430RecruitingPhase 1
CAR T therapy targeting BAFF-R for certain NHL
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120 - NCT05445011RecruitingPhase 1
FLT3-targeted CAR-T for relapsed or resistant AML
This trial tests an engineered immune cell treatment (CAR-T) made to target FLT3, for adults with acute myeloid leukemia (AML) that has come back or did not respond to standard treatment. It aims to control the leukemia when options have been limited.
Wuhan, HubeiAges 18–70 - NCT05450965RecruitingPhase 2
Onvansertib for relapsed small cell lung cancer
This trial studies onvansertib, a targeted medicine, in people whose small cell lung cancer has come back or did not respond to prior platinum chemotherapy. It aims to shrink tumors and improve outcomes after standard treatment has already been tried.
Baltimore, MarylandAges 18 years+ - NCT05472558RecruitingPhase 1
CAR-NK cell treatment for CD19-positive relapsed lymphoma
This Phase 1 study tests a new immune-cell treatment made from donated cord blood. It aims to treat people whose B-cell lymphoma has come back or did not respond, specifically when the tumor has CD19 on it.
Hanzhou, ZhejiangAges 18–75 - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT05477563RecruitingPhase 3
One-time gene therapy for severe sickle cell and transfusion anemia
This trial tests a single dose of gene therapy (CTX001) to improve outcomes for people with severe sickle cell disease or transfusion-dependent beta-thalassemia. It aims to see how well it works and whether it is safe, especially after a planned stem cell transplant process.
New York, New YorkAges 12–35 - NCT05480449RecruitingPhase 1/Phase 2
Personalized CAR-T for children with high-risk B-ALL
This trial studies a personalized type of immune therapy (CAR-T) made from your own cells to treat pediatric B-ALL that has returned or not responded to prior treatment. It aims to see how well this manufactured CAR-T works and how safely it can be given.
Philadelphia, PennsylvaniaAges birth–29 years - NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years - NCT05536141RecruitingPhase 1
Study of AB521 for kidney cancer and other solid tumors
This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.
Birmingham, AlabamaAges 18 years+ - NCT05548621Recruiting
Using shared decision-making tools for kidney cancer care
This study tests whether a shared decision-making approach—using decision aids and guided discussions—helps people make better choices for kidney cancer treatment. It may help you feel more informed and involved when you and your care team decide on next steps.
Nieuwegein, UtrechtAges 18 years+ - NCT05570825RecruitingPhase 2
Study drug SX-682 with pembrolizumab for advanced lung cancer
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Seattle, WashingtonAges 18 years+ - NCT05588453RecruitingPhase 1/Phase 2
Immunotherapy and temozolomide for melanoma brain metastases
This early-phase study tests an immune cell treatment (natural killer cells) plus temozolomide to treat melanoma that has spread to the brain. It’s for people whose brain spots are getting worse and who are not good candidates for certain types of brain radiation.
Columbus, OhioAges 18 years+ - NCT05615636RecruitingPhase 2
Study of four medicines for relapsed B-cell lymphoma
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Houston, TexasAges 18 years+ - NCT05620342RecruitingEarly Phase 1
CAR T-cell therapy for GD2-positive lung cancer
This early-phase study tests a customized immune-cell treatment (CAR T cells) that targets a protein called GD2 on lung cancer cells. It may help people with certain lung cancers that did not respond to platinum chemotherapy and who have also had treatment that blocks PD-1/PD-L1.
Chapel Hill, North CarolinaAges 18 years+ - NCT05620680Recruiting
CD7 CAR-T for relapsed or resistant T-cell cancers
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
Shenzhen, GuangdongAges 18–75 - NCT05621837Recruiting
Biomarker study to guide treatment for several advanced cancers
This study measures how strongly your immune system is being suppressed and uses that information to help personalize cancer treatment. It mainly looks at people with certain advanced cancers and needs tumor tissue and follow-up to check possible immune-related markers.
MilanAges 18–90 - NCT05641428RecruitingPhase 2
Testing a made-at-bedside CAR T cell for relapsed lymphoma
This Phase 2 study compares a “point-of-care” CAR T-cell treatment made at the hospital right away versus standard commercial CAR T-cells. It’s for adults with relapsed or refractory large B-cell lymphoma (a type of blood cancer) to see which approach works best and is safe.
AmsterdamAges 18 years+ - NCT05641935RecruitingPhase 2
Ultrasound scan to check kidney cancer return after ablation
This study tests whether a special ultrasound scan with contrast can help doctors find kidney cancer that comes back after a procedure called ablation. It may help improve monitoring by comparing the ultrasound results with CT or MRI scans done soon after treatment.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,684 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.